Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8922768 | 1.00 | RAB9A (0.62) | RAB9ANPC1TP53SMN1; SMN2CA2 | |
| SCHEMBL31530471 | 0.86 | RAB9A (0.57) | RAB9ANPC1TP53SMN1; SMN2MEN1 | |
| SCHEMBL4488971 | 0.85 | RAB9A (0.62) | RAB9ANPC1TP53SMN1; SMN2CA2 | |
| SCHEMBL11103438 | 0.84 | CA2 (0.71) | RAB9ANPC1SMN1; SMN2CA2CA1 | |
| SCHEMBL11103451 | 0.84 | CA2 (0.71) | RAB9ANPC1SMN1; SMN2CA2CA1 | |
| SCHEMBL10820796 | 0.84 | ALOX5 (0.53) | RAB9ASMN1; SMN2CA2CA1MEN1 | |
| SCHEMBL789411 | 0.84 | ALOX5 (0.53) | RAB9ASMN1; SMN2CA2CA1MEN1 | |
| SCHEMBL11163745 | 0.83 | RAB9A (0.61) | RAB9ANPC1TP53SMN1; SMN2CA2 | |
| SCHEMBL5501691 | 0.82 | RAB9A (0.59) | RAB9ANPC1TP53SMN1; SMN2CA2 | |
| SCHEMBL2251023 | 0.82 | KMT2A (0.58) | TP53SMN1; SMN2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9124595-A | — | — | None | — | — | JP | disclosed |
| JP-6107602-A | — | — | None | — | — | JP | disclosed |
| EP-1492778-A1 | (4,2-DISUBSTITUTED-THIAZOL-5-YL)AMINE COMPOUNDS AS PDE7 INHIBITORS | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6753340-B2 | AUTOIMMUNE DISEASE, ANTIARTHRITIC AGENTS, ANTIALLERGENS, ANTICANCER AGENTS | WARNER-LAMBERT COMPANY LLC | 2004-06-22 | — | — | US | disclosed |
| US-20030191167-A1 | (4,2-Disubstituted-thiazol-5-yl)amine compounds as PDE7 inhibitors | WARNER-LAMBERT COMPANY LLC | 2003-10-09 | — | — | US | disclosed |
| WO-2003082839-A1 | (4,2-DISUBSTITUTED-THIAZOL-5-YL)AMINE COMPOUNDS AS PDE7 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-1348701-A1 | (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors | Warner-Lambert Company LLC (US) | 2003-10-01 | — | — | EP | disclosed |
| JP-H09124595-A | REAGENT FOR OPTICAL RESOLUTION AND PRODUCTION OF OPTICALLY ACTIVE 3-AMINOPYRROLIDINE DERIVATIVE | TORAY IND INC | 1997-05-13 | — | — | JP | disclosed |
| JP-H06107602-A | PRODUCTION OF OPTICALLY ACTIVE 1-PHENYLETHYLAMINE | TORAY IND INC | 1994-04-19 | — | — | JP | disclosed |
| US-4412992-A | 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith | BIOREX LABORATORIES LIMITED (GB) | 1983-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191167-A1 | (4,2-Disubstituted-thiazol-5-yl)amine compounds as PDE7 inhibitors | PDE7A, PDE9A, PDE3A | RAB9A 1013/4885NPC1 3381/4885TP53 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.